Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of QLC7401 monotherapy in non-familial primary hypercholesterolemia or mixed hyperlipidemia
CTR20260118Phase 3Active
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rbd7022 in hypercholesterolemia and combined dyslipidaemia, sponsored by Suzhou Ribo Life Science Co., Ltd. Primary endpoint: Percent change from baseline in LDL-C at Day 330. Started Mar 2026; status: active.
02
Drugs
rbd7022
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20260118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260118.